Journal
MOLECULAR AND CELLULAR BIOLOGY
Volume 28, Issue 19, Pages 5886-5898Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.01265-07
Keywords
-
Categories
Funding
- LRF
- CRUK
Ask authors/readers for more resources
The phosphoinositide-3 kinase (PI3K)/Akt signal pathway plays a key role in the tumorigenesis of many cancers and in the subsequent development of drug resistance. Using the K562 chronic myelogenous leukemia (CML) cell line and the doxorubicin-resistant derivative lines KD30 and KD225 as models, we observed that enhanced PI3K/Akt activity and the acquisition of chemoresistance correlated unexpectedly with the increased expression and nuclear accumulation of FOXO3a. Moreover, we found that the induction of FOXO3a activity in naive K562 cells was sufficient to enhance PI3K/Akt activity and to confer resistance to the cytotoxic effects of doxorubicin. Conversely, the knockdown of endogenous FOXO3a expression reduced PI3K/Akt activity and sensitized these cells to doxorubicin. Further chromatin immunoprecipitation and promoter mutation analyses demonstrated that FOXO3a regulates the expression of the PI3K catalytic subunit p110 alpha through the activation of a promoter region proximal to a novel untranslated exon upstream from the reported transcription start site of the p110 alpha gene PIK3CA. As was the case for FOXO3a, the expression or knockdown of p110 alpha was sufficient to amplify or reduce PI3K/Akt activity, respectively. Thus, our results suggest that the chronic activation of FOXO3a by doxorubicin in CML cells can enhance survival through a feedback mechanism that involves enhanced p110 alpha expression and hyperactivation of the PI3K/Akt pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available